 |
 |
How about enroll me in this research at the University of Oregon in Portland ? Is it near Seattle ? ..... ;)) lv, j Ed Grskovich wrote: > Posted at: AOL Business > > NeoTherapeutics Completes Site Selection for Neotrofin(TM) Phase 2 > Parkinson's Disease Trial > > Patient enrollment accelerating with expanded program > > IRVINE, Calif., Aug. 23 /PRNewswire/ -- NeoTherapeutics, Inc. (Nasdaq: <A > HREF="aol://4785:NEOT">NEOT</A>; NEOTW) announced today that it has expanded > its Neotrofin phase 2 Parkinson's disease trial to include four additional > clinical locations. New participants include Memorial Hospital of Rhode > Island (Providence), Rush Presbyterian-St. Luke's Medical Center (Chicago), > The Parkinson's Institute (Sunnyvale, CA), and Oregon Health & Science > University (Portland). Ten patients are currently receiving either Neotrofin > or placebo, including seven patients at the Parkinson's and Movement Disorder > Institute at Long Beach Memorial Hospital. > > "With site selection completed, we can now focus on enrolling the additional > patients necessary to complete this clinical study," said F. Jacob Huff, > M.D., Vice President, Medical Affairs of NeoTherapeutics. "We are fortunate > to be working with some of the leading experts in the country in the > treatment of Parkinson's disease, and we expect to gain insights into safety > and dosing in Parkinson's patients from this study." > > "Neotrofin uses the body's own tools to protect, repair and rebuild nerves in > the brain," stated Rajesh C. Shrotriya, M.D., President and Chief Operating > Officer of NeoTherapeutics. "Our drug activates nerve growth factors, which > in addition to helping repair nerves, cause the proliferation of stem cells > that already exist in the brain. Additional growth factors stimulated by > Neotrofin may then cause the differentiation and maturation of these new stem > cells into new neurons, which could repair the damage done by > neurodegenerative conditions such as Parkinson's disease." > > Patients participating in this trial will receive doses of Neotrofin > escalating from 250 mg to 1,000 mg twice per day for twelve weeks. In > addition to extensive assessments of tolerance and safety, the Unified > Parkinson's Disease Rating Scale (UPDRS)-part III (Motor Scale) will be used > as the primary measure of preliminary efficacy. Several other Parkinson's > disease rating scales will be used as secondary efficacy measures. > > Parkinson's disease is one of the major neurodegenerative disorders affecting > more than one million patients in North America alone. The principal > hallmarks of Parkinson's disease are slowness of movement, rigidity and > tremor. Although current treatments provide some symptomatic relief, > Parkinson's disease progresses inexorably, often over 10 to 20 years, to > severe immobility and a bedridden state. > > NeoTherapeutics seeks to create value for stockholders through the > development of central nervous system drugs by its neurology division, in- > licensing and development of anti-cancer drugs through its NeoOncoRx > subsidiary, and the licensing out of new drug targets through its NeoGene > Technologies subsidiary. The Company's most advanced drug, Neotrofin(TM), is > currently being developed for Alzheimer's disease and other neurodegenerative > diseases, such as Parkinson's disease and spinal cord injury. For additional > information visit the Company's web site at www.neotherapeutics.com. > > This press release may contain forward-looking statements regarding future > events and the future performance of NeoTherapeutics that involve risks and > uncertainties that could cause actual results to differ materially. These > risks are described in further detail in the Company's reports filed with the > Securities and Exchange Commission. > > Contacts: > > MEDIA RELATIONS > > Jon Siegal > > Ronald Trahan Associates (RTA) Inc. > > (508) 647-9782, ext. 15 > > INVESTOR RELATIONS > > John McManus > > NeoTherapeutics, Inc. > > (949) 788-6700, ext. 247 > > MAKE YOUR OPINION COUNT - Click Here > > http://tbutton.prnewswire.com/prn/11690X72818987 > > SOURCE NeoTherapeutics, Inc. > > CO: NeoTherapeutics, Inc. > > ST: California > > IN: MTC > > SU: > > 08/23/2001 09:15 EDT http://www.prnewswire.com ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn